Taysha Gene Therapies Inc reports results for the quarter ended in September - Earnings Summary

Taysha Gene Therapies

08/11/2022 14:31

* Taysha Gene Therapies Inc  TSHA.OQ  reported a quarterly
adjusted loss of 64 cents​​ per share for the quarter ended in
September. The mean expectation of fifteen analysts for the
quarter was for a loss of 82 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Taysha Gene Therapies Inc's reported EPS for the quarter
was a
loss of 64 cents​.
    * The mean earnings estimate of analysts had risen by
about 12.4%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Taysha Gene Therapies Inc shares had risen by 3.6% this
quarter and lost 82.8% so far this year.
    * The company reported a quarterly loss of $26.31 million.
    * Wall Street's median 12-month price target for Taysha Gene
Therapies Inc is $21.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 15 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
8 at 02:31 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.82          -0.64          Beat
 Jun. 30 2022      -1.00          -0.84          Beat
 Mar. 31 2022      -1.07          -1.31          Missed
 Dec. 31 2021      -1.25          -1.32          Missed